

DOB:                      Age:                      Specimen:                      Collected:  
Sex:                        Requisition:                      Received:  
Phone:                     Report Status:                     Reported:  
Patient ID:

FASTING: YES

**ADVANCED LIPID PANEL, CARDIO IQ<sup>®</sup>**

FINAL

**CHOLESTEROL, TOTAL, CARDIO IQ<sup>®</sup>**

FINAL

Lab:

Analyte	Value
CHOLESTEROL, TOTAL (2093-3)	130 mg/dL

FINAL

**HDL CHOLESTEROL, CARDIO IQ<sup>®</sup>**

FINAL

Lab:

Analyte	Value
HDL CHOLESTEROL (2085-9)	51 mg/dL

FINAL

**TRIGLYCERIDES, CARDIO IQ<sup>®</sup>**

FINAL

Lab:

Analyte	Value
TRIGLYCERIDES (2571-8)	85 mg/dL

FINAL

**NON-HDL AND CALCULATED COMPONENTS, CARDIO IQ<sup>®</sup>**

FINAL

Lab:

Analyte	Value
LDL-CHOLESTEROL (13457-7)	62 mg/dL

FINAL

Desirable range <100 mg/dL for primary prevention; <70 mg/dL for patients with CHD or diabetic patients with > or = 2 CHD risk factors.

LDL-C is now calculated using the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19):2061-2068

For additional information, please refer to <http://education.QuestDiagnostics.com/faq/FAQ164> (This link is being provided for informational/educational purposes only.)

CHOL/HDL-C RATIO (9830-1)	2.5 calc
---------------------------	----------

FINAL

NON HDL CHOLESTEROL (43396-1)	79 mg/dL (calc)
-------------------------------	-----------------

FINAL

For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.

**LIPOPROTEIN FRACTIONATION ION MOBILITY**

FINAL

Lab:

Analyte	Value
LDL PARTICLE NUMBER (54434-6)	890 nmol/L

FINAL

Risk: Optimal <1138; Moderate 1138-1409; High >1409

LDL SMALL (43727-7)	181 nmol/L
---------------------	------------

FINAL

Risk: Optimal <142; Moderate 142-219; High >219

LDL MEDIUM (86222-7)	196 nmol/L
----------------------	------------

FINAL

Risk: Optimal <215; Moderate 215-301; High >301

HDL LARGE (43729-3)	4179 nmol/L
---------------------	-------------

FINAL

Risk: Optimal >6729; Moderate 6729-5353; High <5353

LDL PATTERN (47213-4)	B Pattern
-----------------------	-----------

FINAL

Risk: Optimal Pattern A; High Pattern B

**LDL PEAK SIZE (17782-4)**

215.6 Angstrom

FINAL

Risk: Optimal &gt;222.9; Moderate 222.9-217.4; High &lt;217.4

Adult cardiovascular event risk category cut points (optimal, moderate, high) are based on adult U.S. reference population. Association between lipoprotein subfractions and cardiovascular events is based on Musunuru et al. ATVB. 2009;29:1975.

For additional information, please refer to <http://education.QuestDiagnostics.com/faq/FAQ134> (This link is being provided for informational/educational purposes only.)

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

**APOLIPOPROTEIN B, CARDIO IQ®**

FINAL

Lab:

Analyte	Value	
<b>APOLIPOPROTEIN B (1884-6)</b>	62	mg/dL
Risk: Optimal < 80 mg/dL; Moderate 80-119 mg/dL; High > or = 120 mg/dL Cardiovascular event risk category cut points (optimal, moderate, high) are based on National Lipid Association recommendations - Davidson et al. J Clin Lipidol. 2011;5:338		

FINAL

**LIPOPROTEIN (a), CARDIO IQ®**

FINAL

Lab:

Analyte	Value	
<b>LIPOPROTEIN (a) (43583-4)</b>	94	nmol/L
Risk: Optimal < 75 nmol/L; Moderate 75-125 nmol/L; High > 125 nmol/L Cardiovascular event risk category cut points (optimal, moderate, high) are based on Marcovina et al. Clin Chem. 2003;49:1785 and Nordestgaard et al. European Heart J. 2010;31:2844 (results of meta-analysis and expert panel recommendations).		

FINAL

**Performing Sites****Key**

Priority Out of Range
 Out of Range
 Pending Result
 Preliminary Result
 Final Result
 Reissued Result

Quest, Quest Diagnostics, the associated logo, Nichols Institute, Interactive Insights and all associated Quest Diagnostics marks are the registered trademarks of Quest Diagnostics. All third party marks - '@' and '™' - are the property of their respective owners. Privacy policy can be found at: <http://questdiagnostics.com/home/privacy-policy/online-privacy.html>. © 2018 Quest Diagnostics Incorporated. All rights reserved.

Patient Information	Specimen Information	Client Information
<b>DOB:</b> <b>AGE:</b> Gender: Phone: Patient ID:	Specimen: Requisition: Lab Ref #: Collected: Received: Reported:	

COMMENTS:      FASTING: YES

### Cardio IQ®

Test Name	Current		Risk/Reference Interval			Units	Historical Result & Risk
	Result & Risk		Optimal	Moderate	High		
	Optimal	Non-Optimal					
<b>LIPID PANEL</b>							
CHOLESTEROL, TOTAL	130		<200	N/A	>=200	mg/dL	
HDL CHOLESTEROL	51		>=40	N/A	<40	mg/dL	
TRIGLYCERIDES	85		<150	150-199	>=200	mg/dL	
LDL-CHOLESTEROL	62		<100	100-129	>129	mg/dL	
CHOL/HDLC RATIO	2.5		<=3.5	3.6-5.0	>5.0	calc	
NON-HDL CHOLESTEROL	79		<130	130-189	>=190	mg/dL (calc)	
<b>LIPOPROTEIN FRACTIONATION, ION MOBILITY</b>							
LDL PARTICLE NUMBER	890		<1138	1138-1409	>1409	nmol/L	
LDL SMALL	181		<142	142-219	>219	nmol/L	
LDL MEDIUM	196		<215	215-301	>301	nmol/L	
HDL LARGE	4179		>6729	6729-5353	<5353	nmol/L	
<b>APOLIPOPROTEINS</b>							
APOLIPOPROTEIN B	62		<80	80-119	>=120	mg/dL	
LIPOPROTEIN (a)	94		<75	75-125	>125	nmol/L	

For details on reference ranges please refer to the reference range/comment section of the report.


Patient Information	Specimen Information	Client Information
<b>DOB:</b> <b>AGE:</b> Gender: Patient ID:	Specimen: Collected: Received: Reported:	

**4myheart Diet & Exercise Coaching Program:** Need help achieving and maintaining an optimal weight? Managing stress? Trying to improve physical fitness levels? The 4myheart program provides support and personalized lifestyle guidance to help improve heart health. Please talk to your provider, visit [4myheart.com](http://4myheart.com) or call 1-800-432-7889 opt 2 to learn more.

**Medical Information For Healthcare Providers:** If you have any questions about any of the tests in our Cardio IQ offering, please call 1-800-432-7889 opt 3 to speak to a clinical liaison. For frequently asked questions, you can also visit us at <http://education.questdiagnostics.com/faq/FAQ134>

Patient Information	Specimen Information	Client Information
<b>DOB:</b> Gender: Patient ID:	<b>AGE:</b> Specimen: Collected: Received: Reported:	

**LIPID SUBCLASS DETAIL FROM ION MOBILITY**



Test Name	Current		Risk/Reference Interval			Units	Historical Result & Risk
	Result & Risk		Optimal	Moderate	High		
	Optimal	Non-Optimal					
<b>LIPOPROTEIN SUBFRACTIONS</b>							
LDL PATTERN		<b>B</b>	A	N/A	B	Pattern	
LDL PEAK SIZE		<b>215.6</b>	>222.9	222.9-217.4	<217.4	Angstrom	

For details on reference ranges please refer to the reference range/comment section of the report.

Patient Information	Specimen Information	Client Information
<b>DOB:</b> <b>AGE:</b> Gender: Patient ID:	Specimen: Collected: Received: Reported:	

Reference Range/Comments

Analyte Name	In Range	Out Range	Reference Range	Lab
LDL PATTERN		<b>B</b>	A Pattern	
Risk: Optimal Pattern A; High Pattern B				
LDL PEAK SIZE		<b>215.6</b>	> OR = 217.4 Angstrom	
Risk: Optimal >222.9; Moderate 222.9-217.4; High <217.4 Adult cardiovascular event risk category cut points (optimal, moderate, high) are based on adult U.S. reference population. Association between lipoprotein subfractions and cardiovascular events is based on Musunuru et al. ATVB. 2009;29:1975. For additional information, please refer to <a href="http://education.QuestDiagnostics.com/faq/FAQ134">http://education.QuestDiagnostics.com/faq/FAQ134</a> (This link is being provided for informational/educational purposes only.) This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.				
LIPOPROTEIN (a)		<b>94</b>	<75 nmol/L	
Risk: Optimal < 75 nmol/L; Moderate 75-125 nmol/L; High > 125 nmol/L Cardiovascular event risk category cut points (optimal, moderate, high) are based on Marcovina et al. Clin Chem. 2003;49:1785 and Nordestgaard et al. European Heart J. 2010;31:2844 (results of meta-analysis and expert panel recommendations).				
APOLIPOPROTEIN B	<b>62</b>		52-109 mg/dL	
Risk: Optimal < 80 mg/dL; Moderate 80-119 mg/dL; High > or = 120 mg/dL Cardiovascular event risk category cut points (optimal, moderate, high) are based on National Lipid Association recommendations - Davidson et al. J Clin Lipidol. 2011;5:338				
CHOL/HDLRATIO	<b>2.5</b>		<5.0 calc	
CHOLESTEROL, TOTAL	<b>130</b>		<200 mg/dL	
HDL CHOLESTEROL	<b>51</b>		>40 mg/dL	
HDL LARGE	<b>4179</b>		3382-9376 nmol/L	
Risk: Optimal >6729; Moderate 6729-5353; High <5353				
LDL MEDIUM	<b>196</b>		122-498 nmol/L	
Risk: Optimal <215; Moderate 215-301; High >301				
LDL PARTICLE NUMBER	<b>890</b>		732-2035 nmol/L	
Risk: Optimal <1138; Moderate 1138-1409; High >1409				
LDL SMALL	<b>181</b>		85-473 nmol/L	
Risk: Optimal <142; Moderate 142-219; High >219				
LDL-CHOLESTEROL	<b>62</b>		<100 mg/dL	
Desirable range <100 mg/dL for primary prevention; <70 mg/dL for patients with CHD or diabetic patients with > or = 2 CHD risk factors. LDL-C is now calculated using the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19): 2061-2068 For additional information, please refer to <a href="http://education.QuestDiagnostics.com/faq/FAQ164">http://education.QuestDiagnostics.com/faq/FAQ164</a> (This link is being provided for informational/educational purposes only.)				
NON HDL CHOLESTEROL	<b>79</b>		<130 mg/dL (calc)	
For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.				
TRIGLYCERIDES	<b>85</b>		<150 mg/dL	

PERFORMING SITE: